Aktis Oncology vs AbbVie

Side-by-side comparison of AI visibility scores, market position, and capabilities

AbbVie leads in AI visibility (81 vs 53)
Aktis Oncology logo

Aktis Oncology

ChallengerHealthcare & Life Sciences

Radiopharmaceuticals

Clinical-stage oncology company completed $318M IPO in Jan 2026 — first biotech IPO of 2026 (Nasdaq: AKTS); Eli Lilly took $100M stake; developing alpha-emitting radiopharmaceutical AKY-1189 targeting Nectin-4 for bladder and other solid tumors.

AI VisibilityBeta
Overall Score
C53
Category Rank
#252 of 596
AI Consensus
78%
Trend
stable
Per Platform
ChatGPT
52
Perplexity
57
Gemini
53

About

Aktis Oncology is a Boston-based clinical-stage oncology company developing alpha-emitting radiopharmaceuticals against prevalent solid tumors. The company completed a $318 million IPO in January 2026 — the first significant biotech IPO of 2026 — pricing 17.65 million shares at $18 each on the Nasdaq under ticker AKTS. Eli Lilly stepped in to purchase $100 million of the offering.

Full profile
AbbVie logo

AbbVie

LeaderHealthcare

General

Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.

AI VisibilityBeta
Overall Score
A81
Category Rank
#16 of 596
AI Consensus
87%
Trend
stable
Per Platform
ChatGPT
86
Perplexity
81
Gemini
85

About

AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.

Full profile

AI Visibility Head-to-Head

53
Overall Score
81
#252
Category Rank
#16
78
AI Consensus
87
stable
Trend
stable
52
ChatGPT
86
57
Perplexity
81
53
Gemini
85
47
Claude
86
54
Grok
83

Key Details

Category
Radiopharmaceuticals
General
Tier
Challenger
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Aktis Oncology
Radiopharmaceuticals

Integrations

Both integrate with
Only AbbVie
AbbVie is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.